Hanitrarimalala Veroniaina
Overview
Explore the profile of Hanitrarimalala Veroniaina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mukhopadhyay S, Veroniaina H, Chimombe T, Han L, Zhenghong W, Xiaole Q
RSC Adv
. 2022 May;
9(61):35566-35578.
PMID: 35528069
Protean mesoporous silica nanoparticles (MSNs) are propitious candidates over decades for nanoscale drug delivery systems due to their unique characteristics, including (but not limited to) changeable pore size, mesoporosity, high...
2.
Pan X, Veroniaina H, Su N, Sha K, Jiang F, Wu Z, et al.
Asian J Pharm Sci
. 2022 Jan;
16(6):687-703.
PMID: 35027949
Genetic diseases seriously threaten human health and have always been one of the refractory conditions facing humanity. Currently, gene therapy drugs such as siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid...
3.
Veroniaina H, Wu Z, Qi X
J Adv Res
. 2021 Oct;
33:201-213.
PMID: 34603790
Introduction: Hypoxic tumor microenvironment (TME) is the major contributor to cancer metastasis, resistance to chemotherapy, and recurrence of tumors. So far, no approved treatment has been available to overcome tumor...
4.
Yang W, Veroniaina H, Qi X, Chen P, Li F, Ke P
Adv Ther (Weinh)
. 2021 Jul;
3(1).
PMID: 34291146
Drug repurpose or reposition is recently recognized as a high-performance strategy for developing therapeutic agents for cancer treatment. This approach can significantly reduce the risk of failure, shorten R&D time,...
5.
Veroniaina H, Pan X, Wu Z, Qi X
Expert Rev Anticancer Ther
. 2021 Apr;
21(8):901-913.
PMID: 33844625
: As a protein-based biomaterial for potential cancer targeting delivery, apoferritin has recently attracted interest.: In this review, we discuss the development of this cage-like protein as an endogenous nanocarrier...
6.
Sha K, Ma Q, Veroniaina H, Qi X, Qin J, Wu Z
Pharm Dev Technol
. 2021 Mar;
26(5):549-558.
PMID: 33688786
Solidification of self-microemulsifying drug delivery systems (SMEDDS) is one of the major trends to promote the transformation of self-microemulsion technology into industrialization. Here, a preliminary curcumin SMEDDS formulation was constructed...
7.
Huang H, Sha K, Veroniaina H, Wu Z, Wu Z, Qi X
Nanoscale
. 2020 Mar;
12(13):7347-7357.
PMID: 32206764
One of the most encountered obstacles for utilizing nano-sized vehicles to implement the in vivo delivery of nucleic acid drugs (NADs) is the possible steric hindrance caused by their intrinsic...
8.
Maviah M, Farooq M, Mavlyanova R, Veroniaina H, Filli M, Aquib M, et al.
AAPS PharmSciTech
. 2020 Mar;
21(3):101.
PMID: 32152890
The hydrophobicity of bioactive molecules poses a considerable problem in the pharmaceutical and the food industry. Using food-based protein nanocarriers is one promising way to deliver hydrophobic molecules. These types...
9.
Ji P, Huang H, Yuan S, Wang L, Wang S, Chen Y, et al.
Adv Healthc Mater
. 2019 Nov;
8(23):e1900911.
PMID: 31701665
Reactive oxygen species (ROS)-mediated apoptosis is considered a crucial therapeutic mechanisms for artesunate (AS). As an Fe(II)-dependent drug, the anticancer effect of AS is often limited due to insufficient Fe(II)...
10.
Juliana F, Kesse S, Boakye-Yiadom K, Veroniaina H, Wang H, Sun M
Molecules
. 2019 Oct;
24(20).
PMID: 31652593
Glaucoma is considered a leading cause of blindness with the human eye being one of the body's most delicate organs. Ocular diseases encompass diverse diseases affecting the anterior and posterior...